226 related articles for article (PubMed ID: 15909255)
21. Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.
Ordaz-Farias A; Muñoz-Garza FZ; Sevilla-Gonzalez FK; Arana-Guajardo A; Ocampo-Candiani J; Treviño-Garza N; Becker I; Camacho-Ortiz A
Am J Trop Med Hyg; 2013 Jan; 88(1):153-6. PubMed ID: 23243111
[TBL] [Abstract][Full Text] [Related]
22. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
23. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
24. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Patole S; Burza S; Varghese GM
Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
[TBL] [Abstract][Full Text] [Related]
25. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.
Mings S; Beck JC; Davidson C; Ondo AL; Shanler SD; Berman J
Am J Trop Med Hyg; 2009 Jan; 80(1):3-5. PubMed ID: 19141829
[TBL] [Abstract][Full Text] [Related]
27. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
28. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
29. Miltefosine and cutaneous leishmaniasis.
Machado PR; Penna G
Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
[TBL] [Abstract][Full Text] [Related]
30. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
31. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Stoeckle M; Holbro A; Arnold A; Neumayr A; Weisser M; Blum J
Acta Trop; 2013 Oct; 128(1):168-70. PubMed ID: 23871798
[TBL] [Abstract][Full Text] [Related]
32. Miltefosine for Indian visceral leishmaniasis.
Agarwal PK
N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12606744
[No Abstract] [Full Text] [Related]
33. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.
Couppié P; Clyti E; Sobesky M; Bissuel F; Del Giudice P; Sainte-Marie D; Dedet JP; Carme B; Pradinaud R
Br J Dermatol; 2004 Dec; 151(6):1165-71. PubMed ID: 15606511
[TBL] [Abstract][Full Text] [Related]
34. Miltefosine: issues to be addressed in the future.
Berman J; Bryceson AD; Croft S; Engel J; Gutteridge W; Karbwang J; Sindermann H; Soto J; Sundar S; Urbina JA
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S41-4. PubMed ID: 16750231
[TBL] [Abstract][Full Text] [Related]
35. [Cutaneous leishmaniasis due to Leishmania major involving the bone marrow in an AIDS patient in Burkina Faso].
Barro-Traoré F; Preney L; Traoré A; Darie H; Tapsoba P; Bassolé A; Sawadogo S; Niamba P; Grosshans E; Geniaux M
Ann Dermatol Venereol; 2008 May; 135(5):380-3. PubMed ID: 18457724
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
[TBL] [Abstract][Full Text] [Related]
37. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
[TBL] [Abstract][Full Text] [Related]
38. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
Eichner S; Thoma-Uszynski S; Herrgott I; Sebald H; Debus A; Tsianakas A; Ehrchen J; Harms G; Simon M; Sunderkötter C; Bogdan C
Eur J Dermatol; 2013 Apr; 23(2):218-23. PubMed ID: 23557633
[TBL] [Abstract][Full Text] [Related]
39. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
de Vallière S; Mary C; Joneberg JE; Rotman S; Bullani R; Greub G; Gillmore JD; Buffet PA; Tarr PE
Am J Trop Med Hyg; 2009 Aug; 81(2):209-12. PubMed ID: 19635871
[TBL] [Abstract][Full Text] [Related]
40. Diffuse skin spread of HIV-associated visceral leishmaniasis: cumbersome diagnostic and therapeutic issues.
Manfredi R; Passarini B; D'Antuono A; Misciali C; Marinacci G; Calza L
G Ital Dermatol Venereol; 2008 Oct; 143(5):339-46. PubMed ID: 18833075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
